Abivax Unveils Promising Outcomes of ABTECT Induction Trials
Abivax, a leading clinical-stage biotechnology company, has exciting news to share regarding its innovative treatment, obefazimod. The latest findings from the ABTECT 8-Week Induction Trials illustrate a noteworthy breakthrough in the management of moderate-to-severe ulcerative colitis. The studies demonstrate that the 50 mg dose of obefazimod generates significant clinical improvements for patients, irrespective of their prior responses to advanced therapies. The results are promising not just for new patients but also for those who have experienced inadequate responses in previous treatments.
Key Highlights of the ABTECT Trial Results
The trials presented data showcasing that the 50 mg dose of obefazimod brought about meaningful enhancements across various clinical endpoints. Notably, those who had not responded adequately to advanced therapies (AT-IR) and those who had received multiple lines of treatments showed improvement in their clinical remission rates. Some of the standout findings include:
- The 50 mg dose demonstrated a placebo-adjusted difference in clinical response of 10% (p=0.0009) in participants with prior AT-IR, and a 22% improvement (p<0.0001) in those without.
- Among patients with no history of inadequate response to treatments, the improvements in clinical response reached 28% (p<0.0001), while those with four prior therapies experienced similar enhancement of 29% (p=0.0242).
- Participants previously failed on JAK inhibitor therapy also noted significant benefits, with a 34% improvement (p=0.0017) noted in clinical responses.
These results testify to the clinical efficacy of obefazimod, emphasizing its potential role in enhancing the standard of care provided to ulcerative colitis patients.
Safety and Tolerance Profile
Importantly, the 8-week trial data also confirms that obefazimod is well tolerated among participants, with no new safety concerns emerging for either the 25 mg or 50 mg doses. The favorable safety profile supports its consideration for long-term use in patients who may have previously struggled with treatment efficacy and adverse effects.
Next Steps for Abivax
In light of these findings, Abivax is dedicated to harnessing this momentum. The company's management is keen to further discuss these insights in an upcoming conference call scheduled at 9:00 a.m. ET / 3:00 p.m. CET. This event is crucial for investors and healthcare professionals interested in the latest improvements in ulcerative colitis management via obefazimod.
About Abivax
Located in France and the United States, Abivax remains at the forefront of biotechnology innovation, focusing on treatments that stabilize the immune response in chronic inflammatory conditions. With its lead candidate, obefazimod (also known as ABX464), currently in Phase 3 trials for treating moderately to severely active ulcerative colitis, the company is firmly committed to improving outcomes for patients.
For inquiries, Patrick Malloy, the Senior Vice President for Investor Relations, can be reached at patrick.malloy@abivax.com or via phone at +1 847 987 4878.
Frequently Asked Questions
What is obefazimod?
Obefazimod is a drug candidate developed by Abivax for the treatment of chronic inflammatory disorders like ulcerative colitis.
What were the results of the ABTECT trials?
The results highlighted significant clinical improvements in ulcerative colitis patients treated with obefazimod, indicating its potential effectiveness.
How well is obefazimod tolerated?
The drug has shown a favorable safety profile, with no new safety signals reported during the trials.
When will Abivax discuss the trial results?
Abivax is hosting a conference call to discuss these results today at 9:00 a.m. ET / 3:00 p.m. CET.
Where can I find more information about Abivax?
For more details about Abivax and its research, you can contact the Investor Relations team or visit their official website.
